The introduction of new therapies for such conditions is a monumental task, particularly when identifying eligible patients is akin to finding a needle in a haystack. This case study explores how Quest Diagnostics, led by its Healthcare Analytics Solutions (HAS) team, leveraged advanced data analytics to overcome these challenges and support the successful commercialization of a groundbreaking therapy for an ultra-rare disease which constitutes 0.44% of all hematological malignancies detected each year.